Gross-to-Net Management header

Bob Steller

Bob Steller

Industry Principal of Life Sciences at Vistex

Bob Steller is an expert in Life Sciences revenue management, operational improvement, and information systems. With 28 years of experience, including 21 years with pharmaceutical companies, Bob leverages his deep knowledge of the industry’s unique requirements to help clients streamline financial processes, and boost overall performance.

More posts by Bob Steller

value based contracting feature image

Anchors Up! Are You Ready To Set Sail On The Value-Based Voyage?

The medical device industry is transforming significantly from simple, disposable products like syringes and wheelchairs to complex, multifunctional devices capable of diagnostics, remote monitoring and direct patient interaction.

November 19, 2024

Read More...

340B Compliance: Making It Pay

340B Compliance: Making It Pay

Do you know a surefire way to eat away at your razor-thin margins? Manual processes involving government compliance.

May 6, 2024

Read More...

Why is it important as a company to understand your net price?

Success in Gross-to-Net Management Affects Your Entire Business

Cookie Cutter Tools Are For Baking, Not Financials Achieving a true net price of a product is a challenge for Life Sciences manufacturers. Gross-to-Net (GTN) is not a simpl...

February 6, 2022

Read More...

determine reimbursements with scenario planning

Think Again. And Again.

December 20, 2021

Read More...

Life Sciences Data, Is it Helping or Hurting?

You’ve Got Data. Is It Helping Or Hurting?

Raise the bar—and the bottom line Opportunity could be staring you in the face, but you might not recognize it. As a Life Sciences company, you have so much data. Are you m...

April 21, 2021

Read More...

Status Quo? No Go for The Life Sciences Supply Chain

It seems like such a logical approach—in a global economy, concentrate the production of low-cost items in low-cost countries, simplify supply chains, and employ lean manuf...

December 14, 2020

Read More...

Outcome based pricing featured image

The Power of Outcome-Based Pricing

In February of 2019, CEOs and senior executives from seven major pharmaceutical companies met with the Senate Finance Committee about drug pricing. During that meeting, Ast...

December 11, 2019

Read More...